Biotechnology - Licensing, Gilead Sciences

Filter

Current filters:

LicensingGilead Sciences

Popular Filters

MacroGenics in deal potentially worth $1 billion with Gilead for DART products

09-01-2013

Privately held US biotech firm MacroGenics has entered into a license agreement with Gilead Sciences…

BiotechnologyGilead SciencesLicensingMacroGenicsResearch

Gilead partners to provide low-cost emtricitabine-based ARVs in developing countries

03-08-2012

Gilead Sciences (Nasdaq: GILD), together with Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab…

Anti-viralsBiotechnologyEmtricitabineGilead SciencesGlobalLicensingMylan LaboratoriesPharmaceuticalPricingProductionRanbaxy LaboratoriesStrides Arcolab

Gilead in another licensing deal with J&J unit for combo HIV/AIDS treatment

16-11-2011

US biotech firm Gilead Sciences (Nasdaq: GILD) has entered into a license agreement with Tibotec Pharmaceuticals,…

Anti-viralsBiotechnologycobicistatEmtrivaGilead SciencesJohnson & JohnsonLicensingPharmaceuticalPrezistaResearchTibotec

Bristol-Myers in licensing deal with Gilead for combination HIV pill

26-10-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a licensing accord with biotech firm…

Anti-viralsBiotechnologyBristol-Myers SquibbcobicistatGilead SciencesLicensingPharmaceuticalReyataz

Gilead collaborates with GlobeImmune to develop vaccine for chronic hepatitis B infection

25-10-2011

Gilead Sciences (Nasdaq: GILD) has entered into an exclusive worldwide license and collaboration agreement…

Anti-viralsBiotechnologyGilead SciencesGlobeImmuneLicensingResearchVaccines

Company Spotlight

ImmunoGen

ImmunoGen

Back to top